Big Wins for Big Pharma: Novartis Bounces Back
In the fourth quarter of 2024, a big Swiss drug maker, Novartis, beat expectations but missed its own yearly goals. It announced a huge 16% jump in net sales. That's $13. 2 billion, way more than the estimated $12. 795 billion. The company's adjusted core operating income also surpassed expectation